世界のヒト免疫不全ウイルス（HIV）-1治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2949
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、ヒト免疫不全ウイルス（HIV）-1治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬）、用途別市場規模（病院、クリニック、研究所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・ヒト免疫不全ウイルス（HIV）-1治療の市場動向
・企業の競争状況、市場シェア
・ヒト免疫不全ウイルス（HIV）-1治療の種類別市場規模（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬）
・ヒト免疫不全ウイルス（HIV）-1治療の用途別市場規模（病院、クリニック、研究所）
・ヒト免疫不全ウイルス（HIV）-1治療の北米市場規模2016-2027（アメリカ、カナダ）
・ヒト免疫不全ウイルス（HIV）-1治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・ヒト免疫不全ウイルス（HIV）-1治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ヒト免疫不全ウイルス（HIV）-1治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・ヒト免疫不全ウイルス（HIV）-1治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（AbbVie, Inc.(U.S.)、Merck & Co., Inc. (U.S.)、Bristol-Myers Squibb Company (U.S.)、Boehringer Ingelheim GmbH (Germany)、Genentech, Inc. (U.S.)、Cipla, Inc. (India)）
・結論

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.

Market Analysis and Insights: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is projected to reach US$ 12560 million by 2026, from US$ 11880 million in 2019, at a CAGR of 0.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market.

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists

Segment by Application
Hospitals
Clinics
Labs

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.4 Entry and Fusion Inhibitors
1.2.5 Protease Inhibitors (PIs)
1.2.6 Integrase Inhibitors
1.2.7 Coreceptor Antagonists
1.3 Market by Application
1.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Perspective (2016-2027)
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Regions
2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Dynamic
2.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends
2.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
2.3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Challenges
2.3.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue
3.1.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
3.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio
3.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2020
3.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Area Served
3.6 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
3.7 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Type
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2022-2027)

5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Application
5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2016-2027)
6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
6.2.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2027)
6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
6.3.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2027)
6.4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
6.4.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2016-2027)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
7.2.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2027)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
7.3.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2027)
7.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
7.4.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
8.2.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
8.3.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region
8.4.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2016-2027)
9.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
9.2.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
9.3.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
9.4.1 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
10.2.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
10.3.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country
10.4.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie, Inc.(U.S.)
11.1.1 AbbVie, Inc.(U.S.) Company Details
11.1.2 AbbVie, Inc.(U.S.) Business Overview
11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.1.5 AbbVie, Inc.(U.S.) Recent Development
11.2 Merck & Co., Inc. (U.S.)
11.2.1 Merck & Co., Inc. (U.S.) Company Details
11.2.2 Merck & Co., Inc. (U.S.) Business Overview
11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.2.5 Merck & Co., Inc. (U.S.) Recent Development
11.3 Bristol-Myers Squibb Company (U.S.)
11.3.1 Bristol-Myers Squibb Company (U.S.) Company Details
11.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development
11.4 Boehringer Ingelheim GmbH (Germany)
11.4.1 Boehringer Ingelheim GmbH (Germany) Company Details
11.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development
11.5 Genentech, Inc. (U.S.)
11.5.1 Genentech, Inc. (U.S.) Company Details
11.5.2 Genentech, Inc. (U.S.) Business Overview
11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.5.4 Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.5.5 Genentech, Inc. (U.S.) Recent Development
11.6 Cipla, Inc. (India)
11.6.1 Cipla, Inc. (India) Company Details
11.6.2 Cipla, Inc. (India) Business Overview
11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
11.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
11.6.5 Cipla, Inc. (India) Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Key Players of Entry and Fusion Inhibitors
Table 5. Key Players of Protease Inhibitors (PIs)
Table 6. Key Players of Integrase Inhibitors
Table 7. Key Players of Coreceptor Antagonists
Table 8. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2016-2021)
Table 12. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2022-2027)
Table 14. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Trends
Table 15. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers
Table 16. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Challenges
Table 17. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints
Table 18. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players (2016-2021)
Table 20. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2020)
Table 21. Ranking of Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
Table 25. Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2016-2021)
Table 29. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2016-2021)
Table 33. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 65. AbbVie, Inc.(U.S.) Company Details
Table 66. AbbVie, Inc.(U.S.) Business Overview
Table 67. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 68. AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 69. AbbVie, Inc.(U.S.) Recent Development
Table 70. Merck & Co., Inc. (U.S.) Company Details
Table 71. Merck & Co., Inc. (U.S.) Business Overview
Table 72. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 73. Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 74. Merck & Co., Inc. (U.S.) Recent Development
Table 75. Bristol-Myers Squibb Company (U.S.) Company Details
Table 76. Bristol-Myers Squibb Company (U.S.) Business Overview
Table 77. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 78. Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 79. Bristol-Myers Squibb Company (U.S.) Recent Development
Table 80. Boehringer Ingelheim GmbH (Germany) Company Details
Table 81. Boehringer Ingelheim GmbH (Germany) Business Overview
Table 82. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 83. Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 84. Boehringer Ingelheim GmbH (Germany) Recent Development
Table 85. Genentech, Inc. (U.S.) Company Details
Table 86. Genentech, Inc. (U.S.) Business Overview
Table 87. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 88. Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 89. Genentech, Inc. (U.S.) Recent Development
Table 90. Cipla, Inc. (India) Company Details
Table 91. Cipla, Inc. (India) Business Overview
Table 92. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product
Table 93. Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021) & (US$ Million)
Table 94. Cipla, Inc. (India) Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Features
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 4. Entry and Fusion Inhibitors Features
Figure 5. Protease Inhibitors (PIs) Features
Figure 6. Integrase Inhibitors Features
Figure 7. Coreceptor Antagonists Features
Figure 8. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Labs Case Studies
Figure 12. Human Immunodeficiency Virus (HIV)-1 Therapeutics Report Years Considered
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions: 2020 VS 2027
Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2022-2027)
Figure 17. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players in 2020
Figure 18. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2020
Figure 20. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2016-2021)
Figure 21. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2022-2027)
Figure 22. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2016-2027)
Figure 24. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2016-2027)
Figure 25. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2016-2027)
Figure 30. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2016-2027)
Figure 31. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2016-2027)
Figure 32. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Region (2016-2027)
Figure 42. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2016-2027)
Figure 50. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2016-2027)
Figure 51. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2016-2027)
Figure 52. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Country (2016-2027)
Figure 58. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. AbbVie, Inc.(U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 62. Merck & Co., Inc. (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 63. Bristol-Myers Squibb Company (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 64. Boehringer Ingelheim GmbH (Germany) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 65. Genentech, Inc. (U.S.) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 66. Cipla, Inc. (India) Revenue Growth Rate in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Global Human Immunodeficiency Virus (HIV) Market Size, Status and Forecast 2021-2027
QYR2104Z2948 2021年4月 90Pages
QYResearch社発行の本調査資料では、ヒト免疫不全ウイルス（HIV）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、外来手術センター、診断センター、在宅医療施設、その他）、主要地域別市場規模（北米、アメ...

世界のヒト免疫不全ウイルス検査市場規模・現状・予測（2021年-2027年）

Global Human Immunodeficiency Virus Testing Market Size, Status and Forecast 2021-2027
QYR2104Z2950 2021年4月 126Pages
QYResearch社発行の本調査資料では、ヒト免疫不全ウイルス検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗体検査、RNA（ウイルス量）検査、抗体抗原検査）、用途別市場規模（診断センター、病院、家庭用）、主要地域別市場規模（北米、アメ...

世界のヒトパピローマウイルス検査市場規模・現状・予測（2021年-2027年）

Global Human papilloma virus Testing Market Size, Status and Forecast 2021-2027
QYR2104Z2956 2021年4月 96Pages
QYResearch社発行の本調査資料では、ヒトパピローマウイルス検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（システム、アッセイキット、サービス）、用途別市場規模（子宮頸がん検診、膣がん検診）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界のヒトパピローマウイルス検査市場規模・現状・予測（2021年-2027年）

世界のヒトマイクロバイオーム治療市場規模・現状・予測（2021年-2027年）

Global Human Microbiome Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2955 2021年4月 99Pages
QYResearch社発行の本調査資料では、ヒトマイクロバイオーム治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（FMT、マイクロバイオーム治療薬）、用途別市場規模（クロストリジウム・ディフィシル、クローン病、炎症性腸疾患、糖尿病、その他）...

世界のヒトパピローマウイルス治療市場規模・現状・予測（2021年-2027年）

Global Human Papillomaviru Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2957 2021年4月 94Pages
QYResearch社発行の本調査資料では、ヒトパピローマウイルス治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫調節剤、角質溶解剤、抗腫瘍剤、シネカテキン）、用途別市場規模（生殖器疣贅、生殖器癌、疣冗長表皮異形成症、口腔乳頭腫、中咽頭...

世界の腫瘍溶解性ウイルス免疫療法市場規模・現状・予測（2021年-2027年）

Global Oncolytic Virus Immunotherapy Market Size, Status and Forecast 2021-2027
QYR2104Z4260 2021年4月 99Pages
QYResearch社発行の本調査資料では、腫瘍溶解性ウイルス免疫療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（腫瘍溶解性ウイルスエンジニアリング、野生型腫瘍溶解性ウイルス）、用途別市場規模（病院、診療所、外来手術センター）、主要地域別市...

世界のヒト血漿由来治療市場規模・現状・予測（2021年-2027年）

Global Human Plasma-Derived Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2961 2021年4月 97Pages
QYResearch社発行の本調査資料では、ヒト血漿由来治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アルブミン、免疫グロブリン、凝固因子、プロトロンビン複合体濃縮物、その他）、用途別市場規模（病院、クリニック、研究センター）、主要地域別...

世界のヒトパピローマウイルス・サイトメガロウイルス治療市場規模・現状・予測（2021年-2027年）

Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z2959 2021年4月 99Pages
QYResearch社発行の本調査資料では、ヒトパピローマウイルス・サイトメガロウイルス治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（医療、手術療法）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界の原発性免疫不全症治療市場規模・現状・予測（2021年-2027年）

Global Primary Immunodeficiency Diseases Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4789 2021年4月 95Pages
QYResearch社発行の本調査資料では、原発性免疫不全症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫グロブリン療法、抗生物質、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界のヒト免疫不全ウイルス（HIV）市場規模・現状・予測（2021年-2027年） HIV (Human immunodeficiency virus) is a retrovirus which causes HIV infection and attacks the CD-4 cells (T-cells) in the immune system of human body. HIV reduces the number of T-cells in the body and makes the immune system vulnerable to life-threatening infections and cancers. An infected person c…
世界のヒト免疫不全ウイルス検査市場規模・現状・予測（2021年-2027年） Human Immunodeficiency Virus Testing is the procedure to test if the patient have the Human Immunodeficiency Virus Market Analysis and Insights: Global Human Immunodeficiency Virus Testing Market The global Human Immunodeficiency Virus Testing market size is projected to reach US$ XX million by 2026…
世界のTNF阻害剤市場規模・現状・予測（2021年-2027年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
世界のシグナル伝達阻害剤市場規模・現状・予測（2021年-2027年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
世界の可逆性モノアミン系抗うつ阻害剤（RIMA）市場規模・現状・予測（2021年-2027年） RIMAs are used as antidepressants. They work by reducing the activity of monoamine oxidase which is a chemical found throughout the body. Monoamine oxidase breaks down noradrenaline (also called norepinephrine) and serotonin and other chemicals made and used by the body and brain. These chemicals ar…